加载中
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
前收盘价
US$1.42
+US$0.03 · +2.16%
盘中时间采用ET。市场数据可能有所延迟。
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
日内区间
当前US$1.42
52周区间
当前US$1.42
盘中时间采用ET。市场数据可能有所延迟。
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
日内区间
当前US$1.42
52周区间
当前US$1.42
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 销货成本 | 669.05万 USD | 2563 USD | 750.62万 USD | 674.99万 USD | 1.3万 USD |
| 毛利 | −669.05万 USD | −2563 USD | −750.62万 USD | −674.99万 USD | −1.3万 USD |
| 研究与开发 | 180.9万 USD | 225.42万 USD | 824.36万 USD | 633.8万 USD | 161万 USD |
| 销售、一般及管理费用 | — | 493.21万 USD | — | 674.6万 USD | 492.8万 USD |
| 营业费用 | 180.9万 USD | 718.63万 USD | 824.36万 USD | 633.77万 USD | 621.8万 USD |
| 利息收入 | 3.21万 USD | 5473 USD | — | — | — |
| 利息支出 | 47.39万 USD | 88.36万 USD | 105.33万 USD | 9.67万 USD | — |
| 折旧和摊销 | 1820 USD | 2563 USD | 3866 USD | 3797 USD | 2331 USD |
| 营业利润 | −849.96万 USD | −718.89万 USD | −1574.97万 USD | −1308.76万 USD | −623.1万 USD |
| 净利润 | −894.97万 USD | −470.63万 USD | −1682.55万 USD | −1327.2万 USD | −543.1万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
